LI-RADS 2017: An update
Corresponding Author
Ania Z. Kielar MD, FRCPC
Royal Victoria Regional Health Center, Barrie, Ontario, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada
Address reprint requests to: A.K., Royal Victoria Regional Health Centre, 501 Georgian Drive, Barrie, ON L4M 6M2, Canada. E-mail: [email protected]Search for more papers by this authorVictoria Chernyak MD, MS
Department of Radiology, Montefiore Medical Center, Bronx, New York, USA
Search for more papers by this authorMustafa R. Bashir MD
Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA, Center for Advanced Magnetic Resonance Development, Duke University Medical Center, Durham, North Carolina, USA, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Search for more papers by this authorRichard K. Do MD, PhD
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Search for more papers by this authorKathryn J. Fowler MD
Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
Search for more papers by this authorDonald G. Mitchell MD, FACR
Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Search for more papers by this authorMilena Cerny MD
Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
Search for more papers by this authorKhaled M. Elsayes MD, PhD
Department of Radiology, MD Anderson Cancer Center, Huston, Texas, USA
Search for more papers by this authorCynthia Santillan MD
Department of Radiology, University of California, San Diego, California, USA
Search for more papers by this authorAya Kamaya MD
Department of Radiology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorYuko Kono MD
Department of gastroenterology, University of California, San Diego, California, USA
Search for more papers by this authorClaude B. Sirlin MD
Department of Radiology, University of California, San Diego, California, USA
Search for more papers by this authorAn Tang MD, Msc, FRCPC
Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
Search for more papers by this authorCorresponding Author
Ania Z. Kielar MD, FRCPC
Royal Victoria Regional Health Center, Barrie, Ontario, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada
Address reprint requests to: A.K., Royal Victoria Regional Health Centre, 501 Georgian Drive, Barrie, ON L4M 6M2, Canada. E-mail: [email protected]Search for more papers by this authorVictoria Chernyak MD, MS
Department of Radiology, Montefiore Medical Center, Bronx, New York, USA
Search for more papers by this authorMustafa R. Bashir MD
Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA, Center for Advanced Magnetic Resonance Development, Duke University Medical Center, Durham, North Carolina, USA, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Search for more papers by this authorRichard K. Do MD, PhD
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Search for more papers by this authorKathryn J. Fowler MD
Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA
Search for more papers by this authorDonald G. Mitchell MD, FACR
Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Search for more papers by this authorMilena Cerny MD
Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
Search for more papers by this authorKhaled M. Elsayes MD, PhD
Department of Radiology, MD Anderson Cancer Center, Huston, Texas, USA
Search for more papers by this authorCynthia Santillan MD
Department of Radiology, University of California, San Diego, California, USA
Search for more papers by this authorAya Kamaya MD
Department of Radiology, Stanford University, Palo Alto, California, USA
Search for more papers by this authorYuko Kono MD
Department of gastroenterology, University of California, San Diego, California, USA
Search for more papers by this authorClaude B. Sirlin MD
Department of Radiology, University of California, San Diego, California, USA
Search for more papers by this authorAn Tang MD, Msc, FRCPC
Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
Search for more papers by this authorAbstract
The computed tomography / magnetic resonance imaging (CT/MRI) Liver Imaging Reporting & Data System (LI-RADS) is a standardized system for diagnostic imaging terminology, technique, interpretation, and reporting in patients with or at risk for developing hepatocellular carcinoma (HCC). Using diagnostic algorithms and tables, the system assigns to liver observations category codes reflecting the relative probability of HCC or other malignancies. This review article provides an overview of the 2017 version of CT/MRI LI-RADS with a focus on MRI. The main LI-RADS categories and their application will be described. Changes and updates introduced in this version of LI-RADS will be highlighted, including modifications to the diagnostic algorithm and to the optional application of ancillary features. Comparisons to other major diagnostic systems for HCC will be made, emphasizing key similarities, differences, strengths, and limitations. In addition, this review presents the new Treatment Response algorithm, while introducing the concepts of MRI nonviability and viability. Finally, planned future directions for LI-RADS will be outlined.
Level of Evidence: 5
Technical Efficacy: Stage 5
J. Magn. Reson. Imaging 2018;47:1459–1474.
Conflict of Interest
Ania Kielar has a research grant from General Electric regarding MRI of the liver for hepatocellular carcinoma. An Tang is supported by a research scholarship from Fonds de Recherche du Québec-Santé and Fondation de l'Association des Radiologistes du Québec (FRQS-ARQ 34939). Mustafa Bashir reports research grants from Siemens Healthcare, GE Healthcare, NGM Biopharmaceuticals, TaiwanJ Pharma, and Madrigal Pharmaceuticals. Mustafa Bashir receives consulting fees from RadMD. Claude Sirlin reports research grants from GE and Siemens.
References
- 1 Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
- 2 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
- 3 Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS((R)) algorithm: CT and MRI. Abdom Radiol 2018; 43: 111–126.
- 4 Tang A, Valasek MA, Sirlin CB. Update on the Liver Imaging Reporting and Data System: What the pathologist needs to know. Adv Anat Pathol. 2015; 22: 314–322.
- 5 Sirlin CB. The LI-RADS adventure—a personal statement. Abdom Radiol 2018; 43: 1–2.
- 6 Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol 2018; 43: 13–25.
- 7 ACR Version 2017 LI-RADS Core version. Available from: chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LIRADS_2017_Core.pdf?la=en. Accessed January 18, 2018.
- 8 Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97–104.
- 9 Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma <2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 56: 1317–1323.
- 10 Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034–1042.
- 11 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol 2018; 43: 101–110.
- 12 Granata V, Fusco R, Avallone A, et al. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget 2017; 8: 51224–51237.
- 13 Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol 2018; 43: 75–81.
- 14 Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 2015; 25: 2859–2868.
- 15 Choi SH, Lee SS, Kim SY, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 2017; 282: 771–781.
- 16 Liu YI, Shin LK, Jeffrey RB, Kamaya A. Quantitatively Defining Washout in Hepatocellular Carcinoma. Am J Roentgenol 2013; 200: 84–89.
- 17 Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018; 286: 29–48.
- 18 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol 2018; 43: 101–110.
- 19 Kim TK, Noh SY, Wilson SR, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 — a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 2017; 23: 280–289.
- 20 Kielar A, Fowler KJ, Lewis S, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol 2018; 43: 218–230.
- 21 Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol 2018; 43: 149–157.
- 22 Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376–382.
- 23EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
- 24 Chernyak V, Tang A, Flusberg M, et al. LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol 2018 Jan; 43: 82–100.
- 25 Sofue K, Burke LMB, Nilmini V, et al. Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5. J Magn Reson Imaging 2017; 46: 783–792.
- 26 Ogihara Y, Kitazume Y, Iwasa Y, et al. Prediction of histological grade of hepatocellular carcinoma using quantitative diffusion-weighted magnetic resonance imaging: a retrospective multi-vendor study. Br J Radiol 2017: 20170728.
- 27 Shankar S, Kalra N, Bhatia A, et al. Role of diffusion weighted imaging (DWI) for hepatocellular carcinoma (HCC) detection and its grading on 3T MRI: A prospective study. J Clin Exp Hepatol 2016; 6: 303–310.
- 28 Choi BI, Lee GK, Kim ST, Han MC. Mosaic pattern of encapsulated hepatocellular carcinoma: correlation of magnetic resonance imaging and pathology. Gastrointest Radiol 1990; 15: 238–240.
- 29 Yoshida T, Matsue H, Okazaki N, Yoshino M. Ultrasonographic differentiation of hepatocellular carcinoma from metastatic liver cancer. J Clin Ultrasound 1987; 15: 431–437.
- 30 Goshima S, Noda Y, Kajita K, et al. Gadoxetic acid-enhanced high temporal-resolution hepatic arterial-phase imaging with view-sharing technique: Impact on the LI-RADS category. Eur J Radiol 2017; 94: 167–173.
- 31 Mitsumori LM, Bhargava P, Essig M, Maki JH. Magnetic resonance imaging using gadolinium-based contrast agents. Top Magn Reson Imaging 2014; 23: 51–69.
- 32 Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638–644.
- 33 Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. RadioGraphics 2009; 29: 1725–1748.
- 34 Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: What to expect? J Hepatol 2012; 57: 421–429.
- 35 Chen L, Zhang L, Bao J, et al. Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut 2013; 62: 1520–1521.
- 36 Niendorf E, Spilseth B, Wang X, Taylor A. Contrast enhanced MRI in the diagnosis of HCC. Diagnostics 2015; 5: 383–398.
- 37 Suh CH, Kim KW, Pyo J, Lee J, Kim SY, Park SH. Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI: A systematic review and meta-analysis. AJR Am J Roentgenol 2017; 209: 781–789.
- 38 Aube C, Oberti F, Lonjon J, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 2017; 37: 1515–1525.
- 39 Neri E, Bali MA, Ba-Ssalamah A, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 2016; 26: 921–931.
- 40 Benson AB 3rd, D'Angelica MI, et al. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Comprehen Cancer Network 2017; 15: 563–573.
- 41EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48: 599–641.
- 42 Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376–382.
- 43 Omata M, Cheng A-L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317–370.
- 44 Renzulli M, Golfieri R. Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol 2016; 31: 69–80.
- 45 Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12: 145.
- 46 Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol 2016; 41: 71–90.
- 47 Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging after percutaneous radiofrequency ablation of hepatic tumors. Part 2. Abnormal findings. Am J Roentgenol 2013; 200: 194–204.
- 48 Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2009; 192: 1675–1681.
- 49 Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017; 16: 564–570.
- 50 Geschwind J-FH. Locoregional therapy for patients with hepatocellular carcinoma. Gastroenterol Hepatol 2015; 11: 698–700.
